These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 8414454

  • 1. [Ursodeoxycholic acid therapy in biliary cirrhosis].
    Herszényi L, Szalay L, Schaff Z, Gergely P, Fehér J.
    Orv Hetil; 1993 Sep 19; 134(38):2085-9. PubMed ID: 8414454
    [Abstract] [Full Text] [Related]

  • 2. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M.
    Am J Gastroenterol; 1990 Jan 19; 85(1):15-23. PubMed ID: 1967512
    [Abstract] [Full Text] [Related]

  • 3. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R.
    Hepatology; 1998 Aug 19; 28(2):296-301. PubMed ID: 9695990
    [Abstract] [Full Text] [Related]

  • 4. Immunologic effects of ursodeoxycholic acid in primary biliary cirrhosis.
    Leevy CB, Holt J, Buniak B.
    J Assoc Acad Minor Phys; 1993 Aug 19; 4(1):30-2. PubMed ID: 8425102
    [Abstract] [Full Text] [Related]

  • 5. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA, Sanai FM, Swain MG.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):813-20. PubMed ID: 16918885
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES.
    Hepatology; 1996 Nov 01; 24(5):1098-103. PubMed ID: 8903382
    [Abstract] [Full Text] [Related]

  • 7. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F, Akarca US, Ersöz G, Karasu Z, Yüce G, Batur Y.
    Hepatogastroenterology; 2002 Nov 01; 49(47):1195-200. PubMed ID: 12239904
    [Abstract] [Full Text] [Related]

  • 8. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB.
    Hepatology; 1996 Jun 01; 23(6):1464-7. PubMed ID: 8675165
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis.
    Wolfhagen FH, van Buuren HR, Schalm SW.
    Neth J Med; 1994 Mar 01; 44(3):84-90. PubMed ID: 8202208
    [Abstract] [Full Text] [Related]

  • 11. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR, Dutch PBC Study Group.
    Gastroenterology; 2009 Apr 01; 136(4):1281-7. PubMed ID: 19208346
    [Abstract] [Full Text] [Related]

  • 12. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
    Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ.
    Hepatology; 2002 Feb 01; 35(2):409-13. PubMed ID: 11826416
    [Abstract] [Full Text] [Related]

  • 13. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon RE, Poupon R.
    Liver Int; 2004 Jun 01; 24(3):187-93. PubMed ID: 15189267
    [Abstract] [Full Text] [Related]

  • 14. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH.
    Liver Transpl; 2007 Sep 01; 13(9):1236-45. PubMed ID: 17763401
    [Abstract] [Full Text] [Related]

  • 15. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
    Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK.
    Aliment Pharmacol Ther; 2005 Feb 01; 21(3):217-26. PubMed ID: 15691295
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
    Avezov SA, Mansurov FKh.
    Klin Med (Mosk); 2004 Feb 01; 82(3):55-8. PubMed ID: 15114777
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE.
    Hepatology; 1999 Jan 01; 29(1):39-43. PubMed ID: 9862847
    [Abstract] [Full Text] [Related]

  • 18. Natural history of pruritus in primary biliary cirrhosis.
    Talwalkar JA, Souto E, Jorgensen RA, Lindor KD.
    Clin Gastroenterol Hepatol; 2003 Jul 01; 1(4):297-302. PubMed ID: 15017671
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
    Avezov SA, Mansurova FKh.
    Klin Med (Mosk); 2004 Jul 01; 82(2):46-9. PubMed ID: 15106512
    [Abstract] [Full Text] [Related]

  • 20. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD.
    Hepatology; 1999 Mar 01; 29(3):644-7. PubMed ID: 10051462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.